CA
MYGN icon

Callahan Advisors’s Myriad Genetics MYGN Stock Holding History

Callahan Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,745
Closed -$230K – 117
2014
Q4 		$230K Sell
6,745
-725
-10% -$25.7K 0.07% 112
2014
Q3 		$288K Buy
7,470
+1,025
+16% +$38.2K 0.09% 107
2014
Q2 		$251K Buy
+6,445
New +$240K 0.08% 113

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Callahan Advisors's MYGN Position: Q1 2015 in Review

Callahan Advisors sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 6,745 shares — an estimated $230K sold.

Callahan Advisors first reported a position in MYGN in Q2 2014 and held it in 3 quarters. The position peaked at $288K in Q3 2014. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

  • Callahan Advisors reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
  • Callahan Advisors sold 6,745 Myriad Genetics shares in Q1 2015, an estimated $230K.
  • Callahan Advisors first reported a position in Myriad Genetics in Q2 2014 and held it in 3 quarters.
  • Callahan Advisors's Myriad Genetics position peaked at $288K in Q3 2014.
  • 251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Callahan Advisors's 13F filing for Q1 2015, filed 20 Apr 2015.